Genmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, while ruling out any interest in a merger with big pharma.
Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer.
AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk
